Background: As many patients with unipolar depression do not respond sufficiently to initial antidepressant monotherapy, a dose increase of the current administered antidepressant (dose escalation, high-dose treatment) is frequently carried out as next treatment measure. Methods: We conducted a meta-analysis which included all double-blind randomized controlled trials (RCTs) comparing a dose increase of antidepressants directly to continuation of standard-dose treatment in unipolar depressive patients who were non- responders to standard-dose pharmacotherapy. A mean change in the Hamilton Rating Scale for Depression (HAM-D) total score was the primary outcome. Secondary outcomes were response rates and discontinuation rates due to any reason, inefficacy, and adverse effects. Hedges g and risk ratios were calculated as effect sizes. Results: Seven double-blind RCTs (8 study arms) representing 1,208 participants were included. Fluoxetine (N [number of studies] = 2, n [number of patients] = 448), sertraline (N = 2, n = 272), paroxetine (N = 2, n = 146), duloxetine (N = 1, n = 255), and maprotiline (N = 1, n = 87) were investigated. Dose escalation was not more efficacious in HAM-D total score reduction than maintaining standard-dose treatment, neither for the pooled antidepressant group (N = 7, n = 999; Hedges g = -0.04, 95% CI: -0.20 to 0.12; p = 0.63) nor the individual antidepressants. No differences could be determined for response rates, all-cause discontinuation, and drop-outs due to inefficacy. Significantly more patients in the dose escalation group dropped out due to adverse effects than in the standard-dose continuation group. The metaregressions indicate no influence of baseline symptom severity or amounts of dose increments on effect sizes. Conclusions: According to our meta-analytic findings, dose escalation after initial non-response to standard-dose pharmacotherapy cannot be regarded as general evidence-based treatment option in unipolar depression.

Keywords:
Depression, Antidepressants, Treatment resistance, Non-response, High-dose treatment
1.
APA: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, ed 3. Arlington, American Psychiatric Association, 2010.
2.
Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. 1. Update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013;14:334-385.
3.
Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, Moller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. 2. Maintenance treatment of major depressive disorder - update 2015. World J Biol Psychiatry 2015;16:76-95.
4.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-758.
5.
Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lepine JP, Moller HJ, Nutt DJ, Rouillon F, Schatzberg AF, Thase ME: Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323-329.
6.
Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J: Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91.
7.
Souery D, Papakostas GI, Trivedi MH: Treatment-resistant depression. J Clin Psychiatry 2006;67(suppl 6):16-22.
8.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
9.
Kasper S, Montgomery S: Treatment-Resistant Depression. Chichester, Wiley-Blackwell, 2013.
10.
Dold M, Kautzky A, Bartova L, Rabl U, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S: Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - a pharmacoepidemiological cross-sectional multicenter study. Eur Neuropsychopharmacol 2016;26:1960-1971.
11.
NICE: Depression in Adults: The Treatment and Management of Depression in Adults. London National Collaborating Centre for Mental Health, 2009.
12.
Adli M, Baethge C, Heinz A, Langlitz N, Bauer M: Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005;255:387-400.
13.
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G: AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44:195-235.
14.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
15.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. BMJ 2009;339:b2535.
16.
Der-Simonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
17.
Egger M, Davey S, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
18.
Borenstein M, Hedges L, Higgins J, Rothstein H: Comprehensive Meta-Analysis, version 2. Englewood, Biostat, 2006.
19.
The Cochrane Collaboration: Software Review Manager (Revman), version 5.2. Oxford, The Cochrance Collaboration, 2014.
20.
Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.1 (updated online march 2011). Chichester, Wiley & Sons, 2011.
21.
Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF: Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989;25:71-79.
22.
Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C: What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990;51:8-11.
23.
Schweizer E, Rynn M, Mandos LA, Demartinis N, Garcia-Espana F, Rickels K: The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 2001;16:137-143.
24.
Licht RW, Qvitzau S: Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology 2002;161:143-151.
25.
Benkert O, Szegedi A, Wetzel H, Staab HJ, Meister W, Philipp M: Dose escalation vs continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 1997;95:288-296.
26.
Ruhe HG, Booij J, van Weert HC, Reitsma JB, Franssen EJ, Michel MC, Schene AH: Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2009;34:999-1010.
27.
Kornstein SG, Dunner DL, Meyers AL, Whitmyer VG, Mallinckrodt CH, Wohlreich MM, Detke MJ, Hollandbeck MS, Greist JH: A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry 2008;69:1383-1392.
28.
Cohen J: Statistical Power Analysis for the Behavioural Sciences. New York, Academic Press, 1969.
29.
Dold M, Kasper S: Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract 2017;21:13-23.
30.
Ruhe HG, Huyser J, Swinkels JA, Schene AH: Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 2006;189:309-316.
31.
Baker CB, Tweedie R, Duval S, Woods SW: Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety 2003;17:1-9.
32.
Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF: Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002;22:379-387.
33.
Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM: Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-1374.
34.
Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S: Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-835.
35.
Erb SJ, Schappi JM, Rasenick MM: Antidepressants accumulate in lipid rafts independent of monoamine transporters to modulate redistribution of the G protein, Gαs. J Biol Chem 2016;291:19725-19733.
36.
Hieronymus F, Emilsson JF, Nilsson S, Eriksson E: Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2016;21:523-530.
37.
Adli M, Pilhatsch M, Bauer M, Koberle U, Ricken R, Janssen G, Ulrich S, Bschor T: Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry 2008;41:252-257.
38.
Amsterdam JD, Berwish NJ: High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 1989;22:21-25.
39.
Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016;85:270-288.
40.
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015;84:72-81.
41.
Fava GA: Rational use of antidepressant drugs. Psychother Psychosom 2014;83:197-204.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.